Skip to main content

Agilent Technologies, Inc. (A) Stock Analysis

HoldModerate Confidence

Healthcare · Diagnostics & Research

Earnings in 7 days (2026-05-27). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Hold if already holding. Not a fresh buy at $110.57, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Weak growth.

Agilent Technologies provides instruments, software, services, and consumables for laboratory workflows across life sciences, diagnostics, and applied markets through three segments globally, with approximately 18,100 employees. Revenue is earned from pharmaceutical,... Read more

$110.57+31.1% A.UpsideScore 5.3/10#17 of 26 Diagnostics & Research
QualityF-score8 / 9FCF yield2.74%
IncomeYield0.92%(5y avg 0.67%)Payout22.05%sustainable
Stop $106.89Target $144.96(analyst − 10%)A.R:R 5.0:1
Analyst target$161.07+45.7%15 analysts
$144.96our TP
$110.57price
$161.07mean
$185

Hold if already holding. Not a fresh buy at $110.57, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 5.3/10, moderate confidence.

Passes 5/9 gates (favorable risk/reward ratio, clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA) and earnings proximity 7d<=7d. Suitability: moderate.

Recent Developments — Agilent Technologies, Inc.

Material events (past 30 days)

  • May 4, 2026 MEDIUM Item 5.02: Bret DiMarco resigned as SVP, Chief Legal Officer and Secretary effective May 4, 2026; Michael Buckner appointed as new CLO same date. DiMarco to remain as Special Advisor through December 1, 2026. Clean handoff.

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
V7 quality resilience bonus: +0.2 (Q=7.2 in RISK_OFF)
Sector modifier (Healthcare): +0.5
High-quality business
Risks
Earnings in 7 days (event risk)
Weak growth
Negative momentum

Key Metrics

P/E (TTM)24.4
P/E (Fwd)16.8
Mkt Cap$31.2B
EV/EBITDA16.8
Profit Mgn18.3%
ROE19.9%
Rev Growth7.0%
Beta1.22
Dividend0.92%
Rating analysts28

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C0.85neutral
IV48%normal
Max Pain$220+99.0% vs spot

Material Events(8-K, last 90d)

  • 2026-05-04Item 5.02MEDIUM
    Bret DiMarco resigned as SVP, Chief Legal Officer and Secretary effective May 4, 2026; Michael Buckner appointed as new CLO same date. DiMarco to remain as Special Advisor through December 1, 2026. Clean handoff.
    SEC filing →
  • 2026-04-03Item 5.02MEDIUM
    Bret DiMarco (CLO) entered transition agreement March 31, 2026; will resign upon new CLO appointment or September 30, 2026. No successor named at time of filing.
    SEC filing →
  • 2026-03-06Item 5.02LOW
    Rodney Gonsalves (VP Corporate Controller and PAO) notified Agilent of retirement effective January 2027. No successor named; departure not related to any disagreement with the company.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Ma Position
1.5
Rsi
4.5
Volume
6.7
Volume distribution (falling OBV)Below 200-MA, MA slope flat

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
1.3
Revenue Growth
4.2
GatesMomentum 2.7<4.5Death cross (50MA < 200MA)EARNINGS PROXIMITY 7d<=7dExecutive change: officer departure/appointmentA.R:R 5.0 ≥ 1.5Insider activity: OKNEWS EVENTS NONE RECENTSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Moderate
RSI
49 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $110.20Resistance $123.30

Price Targets

$107
$145
A.Upside+31.1%
A.R:R5.0:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeRisk-Off

Risk Alerts

! Momentum score 2.7/10 — below 4.5 minimum
! Death cross — 50-day MA below 200-day MA
! EARNINGS_PROXIMITY:7d<=7d

Earnings

B
B
M
M
2/4 beats
Next Earnings2026-05-27 (7d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is A stock a buy right now?

Hold if already holding. Not a fresh buy at $110.57, but acceptable to hold if already in. Reasons: Earnings in 7 days (event risk); Weak growth. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $144.96 (+31.1%), stop $106.89 (−3.4%), A.R:R 5.0:1. Score 5.3/10, moderate confidence.

What is the A stock price target?

Take-profit target: $144.96 (+31.1% upside). Target $144.96 (+31.1%), stop $106.89 (−3.4%), A.R:R 5.0:1. Stop-loss: $106.89.

What are the risks of investing in A?

Earnings in 7 days (event risk); Weak growth; Negative momentum.

Is A overvalued or undervalued?

Agilent Technologies, Inc. trades at a P/E of 24.4 (forward 16.8). TrendMatrix value score: 6.4/10. Verdict: Hold.

What do analysts say about A?

28 analysts cover A with a consensus score of 4.0/5. Average price target: $161.

What does Agilent Technologies, Inc. do?Agilent Technologies provides instruments, software, services, and consumables for laboratory workflows across life...

Agilent Technologies provides instruments, software, services, and consumables for laboratory workflows across life sciences, diagnostics, and applied markets through three segments globally, with approximately 18,100 employees. Revenue is earned from pharmaceutical, biopharmaceutical, academic, government, chemicals, food, and environmental customers via direct sales, distributors, and resellers.

Related stocks: VCYT (Veracyte, Inc.) · SHC (Sotera Health Company) · GH (Guardant Health, Inc.) · MEDP (Medpace Holdings, Inc.) · NTRA (Natera, Inc.)